Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
Trial Parameters
Brief Summary
The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility in the pilot phase of performing real-time drug screening on tissue taken during surgery in patients with relapsed medulloblastoma or ependymoma and of having a specialized tumor board assign a treatment plan based on the results of this screening and genomic sequencing. The aim of this trial is to allow every child and young adult with relapsed medulloblastoma and ependymoma to receive the most effective and least toxic therapies currently available and will pave the way for improved understanding and treatment of these tumors in the future. Moreover, if successful, it could serve as a paradigm for personalized medicine programs for other types of cancer.
Eligibility Criteria
Inclusion Criteria: 1. Participants must have recurrent medulloblastoma or recurrent ependymoma previously histologically confirmed. Participants must be experiencing their first or second relapse to be eligible. 2. Participants must have surgically accessible disease. 3. Prior Therapy: 1. The participant must have received at least one prior therapy at the time of initial diagnosis. 2. Relapsed medulloblastoma or relapsed ependymoma are eligible. 3. Participants must have fully recovered from the acute toxic effects of all prior chemotherapy, immunotherapy, or radiotherapy prior to entering this study and would be eligible for surgical resection per institutional guidelines * Participants must have received last chemotherapy or biologic agent at least 7 days prior to registration. * Monoclonal antibody treatment: \> 21 days prior to registration. * Bevacizumab participants must have received last dose \> 21 days prior to study registration 4. Participant must be a candidate for surgic